198 related articles for article (PubMed ID: 29048623)
21. Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-γ.
Chen CL; Chiang TH; Tseng PC; Wang YC; Lin CF
Biochem Biophys Res Commun; 2015 Oct; 466(3):578-84. PubMed ID: 26385178
[TBL] [Abstract][Full Text] [Related]
22. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels.
Lee JY; Hong SH; Shin M; Heo HR; Jang IH
Biochem Biophys Res Commun; 2016 Sep; 478(2):733-8. PubMed ID: 27507214
[TBL] [Abstract][Full Text] [Related]
23. Anticancer function of α-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression.
Zhang F; Yang R; Zhang G; Cheng R; Bai Y; Zhao H; Lu X; Li H; Chen S; Li J; Wu S; Li P; Chen X; Sun Q; Zhao G
Tumour Biol; 2016 May; 37(5):6437-46. PubMed ID: 26631041
[TBL] [Abstract][Full Text] [Related]
24. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
25. An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.
Chang GC; Yu CT; Tsai CH; Tsai JR; Chen JC; Wu CC; Wu WJ; Hsu SL
Eur J Pharmacol; 2008 Dec; 600(1-3):37-44. PubMed ID: 18973751
[TBL] [Abstract][Full Text] [Related]
26. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
27. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression.
Wang R; Zhang J; Chen S; Lu M; Luo X; Yao S; Liu S; Qin Y; Chen H
Lung Cancer; 2011 Nov; 74(2):188-96. PubMed ID: 21601305
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of FOXP3 inhibits cell proliferation and enhances chemosensitivity to cisplatin in human lung adenocarcinoma.
Li C; Sun L; Jiang R; Wang P; Xue H; Zhan Y; Gai X
Pathol Res Pract; 2017 Oct; 213(10):1251-1256. PubMed ID: 28935177
[TBL] [Abstract][Full Text] [Related]
29. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
30. miRNA‑328 overexpression confers cisplatin resistance in non‑small cell lung cancer via targeting of PTEN.
Wang C; Wang S; Ma F; Zhang W
Mol Med Rep; 2018 Nov; 18(5):4563-4570. PubMed ID: 30221716
[TBL] [Abstract][Full Text] [Related]
31. Regulation of inflammation- and angiogenesis-related gene expression in breast cancer cells and co-cultured macrophages.
Burnett GT; Weathersby DC; Taylor TE; Bremner TA
Anticancer Res; 2008; 28(4B):2093-9. PubMed ID: 18751381
[TBL] [Abstract][Full Text] [Related]
32. Effect of exogenous p51a gene on the growth and chemo sensitivity of human lung adenocarcinoma cell lines.
Shen Q; Wang H; Zhang L
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S383-S388. PubMed ID: 30095026
[TBL] [Abstract][Full Text] [Related]
33. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
34. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
35. TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
Lv Y; Huo Y; Yu X; Liu R; Zhang S; Zheng X; Zhang X
Drug Des Devel Ther; 2016; 10():3053-3064. PubMed ID: 27729767
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
37. β-Elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome.
Li J; JunYu ; Liu A; Wang Y
Lung Cancer; 2014 Nov; 86(2):144-50. PubMed ID: 25204604
[TBL] [Abstract][Full Text] [Related]
38. Reversal of galectin-1 gene silencing on resistance to cisplatin in human lung adenocarcinoma A549 cells.
Zhang L; Liu X; Tang Z; Li X; Wang G
Biomed Pharmacother; 2016 Oct; 83():265-270. PubMed ID: 27392028
[TBL] [Abstract][Full Text] [Related]
39. Alantolactone induces apoptosis, promotes STAT3 glutathionylation and enhances chemosensitivity of A549 lung adenocarcinoma cells to doxorubicin via oxidative stress.
Maryam A; Mehmood T; Zhang H; Li Y; Khan M; Ma T
Sci Rep; 2017 Jul; 7(1):6242. PubMed ID: 28740138
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin.
Abdulrahman N; Jaballah M; Poomakkoth N; Riaz S; Abdelaziz S; Issa A; Mraiche F
Mol Cell Biochem; 2016 Jul; 418(1-2):21-9. PubMed ID: 27236820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
